Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. - Wikidata - wikimedia - TriplyDB

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.

http://www.wikidata.org/entity/Q33340568

about

UK guidelines for the management of bone sarcomas Advances in the management of osteosarcoma Anti-osteosarcoma effects and mechanisms of 4-O-amino-phenol-4'-demethylepipodophyllotoxin ether.Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.Strategies for the targeted delivery of therapeutics for osteosarcoma.Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group Pathological fractures in predicting clinical outcomes for patients with osteosarcoma.Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.Chemotherapy resistance in osteosarcoma: current challenges and future directions.Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.Complications and risk factors for failure of rotationplasty: review of 25 patients.Adult human sarcomas. II. Medical oncology.Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group Current concepts on the surgical and medical management of osteosarcoma.Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort.Mifamurtide for the treatment of nonmetastatic osteosarcoma The adolescent and young adult with cancer: state of the art -- bone tumors.Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going?Current therapeutic strategies and novel approaches in osteosarcoma.Review of management issues in relapsed osteosarcoma.The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.Metastatic osteosarcoma: a challenging multidisciplinary treatment.Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.Risk-Based Therapy for Localized Osteosarcoma.High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma.A novel EWSR1-CREB3L1 fusion transcript in a case of small cell osteosarcoma.Osteosarcoma: Accelerating Progress Makes for a Hopeful Future.Bilateral synchronous tibial periosteal osteosarcoma with familial incidence.Mitoxantrone induces apoptosis in osteosarcoma cells through regulation of the Akt/FOXO3 pathway.Progress in the chemotherapeutic treatment of osteosarcoma

P2860

Q26752425-4C6578CC-80CC-42E6-A6B3-2A7CC42A2223 Q28067644-34BA670A-7FC4-405C-807A-233319AE4FCA Q33317664-F945A5DE-67BD-4D40-827F-F378E08A6A82 Q33395803-B9639FB3-0D01-44DC-93EE-D5E3F8D7B747 Q33418510-9D25206E-430B-468F-9BEE-6A2EE7448678 Q33434899-5A7F1EAB-0750-446C-8194-D41A0B33E062 Q34179495-23F43BEC-3BD9-4C1E-9754-4D7BAF870A37 Q34413741-AD21B829-235B-4E43-BE2C-E80DADAF12F0 Q34588395-98560DFE-74AB-4501-A1ED-B5E46700A971 Q35005741-34D6B027-8A87-4E7C-8041-23264DE5D2CE Q35848126-EC4F0457-3CCC-4AFB-86EE-22A2983062B2 Q35942323-8BB54FCF-B448-441E-8D98-DF68F609B74E Q35945493-0368A6BB-56F5-4D5E-9290-A249AE189196 Q36097717-87DAC80B-CD76-47FB-A304-AADEE898E827 Q36235053-6F7E420F-E4CD-4011-86B5-ED6BBBF33622 Q36512499-B6100F81-8B53-4C10-A11C-B3242A7317CE Q36532115-F3D03057-5C67-4114-809F-61AB078739A9 Q36653789-DF305662-ADB9-420A-BD4A-D99468749774 Q36657806-8186FA52-C672-4BA6-947B-40982CE21CB7 Q36731430-2AD20160-ABC0-496F-A5F9-809FF2A8FA82 Q36946864-9EA6BB03-8AF2-4D39-8C49-D77575D32FD6 Q37242673-B7F1640F-7C45-4B7F-8EAD-144CB77159BA Q37265109-88684669-B2E4-4078-B044-AB36DB92AB9F Q37396718-713CE122-57C8-4EA4-B03D-39CDF22B5577 Q37827876-77A79EBB-724F-4863-AF9D-051502A1C295 Q38108248-0A2D2BC6-B97E-4EB8-B253-EBD7A1AEFD9D Q38126943-07E679BE-B049-444D-A000-C55FE2778511 Q38161735-A3A23F19-94E5-41CE-B76E-B53C76663AC1 Q38168922-69E9348B-3E48-4A74-A7D2-DC223B5BB126 Q38267782-DDC6AD7A-DC44-4E8F-8170-BC047EC06401 Q38689748-16B69039-751A-4F97-81E5-26DACF4CC299 Q38783252-B92BFF4D-72F2-4382-AF85-88223A40D813 Q38791215-2777CB5E-B0E5-4BE3-87EC-EA9C650947C4 Q41185936-C217055A-F5C5-4C44-B357-2571E350258A Q41882645-E61F3637-5242-4477-A24A-6F868CDB094D Q45333567-83263BC0-920E-4EAE-9429-89169747A82A Q49484270-6E2C0A1E-7760-431C-AC62-BF8A4AF8F5E6 Q51358886-D2738857-0F3E-4221-B481-B7C7433F010F Q55180297-08C101A8-C92F-4FE3-B82F-31921FEA130E Q58572917-25FBC673-0D25-41C0-A442-DB31A5691FFD

P2860

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.

http://www.wikidata.org/entity/Q33340568

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Phase II/III trial of etoposid ...... ediatric oncology group trial.

@ast

Phase II/III trial of etoposid ...... ediatric oncology group trial.

@en

type

label

Phase II/III trial of etoposid ...... ediatric oncology group trial.

@ast

Phase II/III trial of etoposid ...... ediatric oncology group trial.

@en

prefLabel

Phase II/III trial of etoposid ...... ediatric oncology group trial.

@ast

Phase II/III trial of etoposid ...... ediatric oncology group trial.

@en

P1433

Q33340568-F15BE750-E13E-499A-8ADB-2FD59A5B7C84

P1476

Q33340568-64DF0DCB-E577-4BBC-9518-34EAD15A869D

P2093

Q33340568-0AC28963-BA83-4441-B39A-6E435C5FDD6A

Q33340568-118E6C6B-FA55-4807-A5D1-12F1EE22E1CA

Q33340568-15EEBEEF-7B4A-4362-A659-ECA2501F621C

Q33340568-19311575-F370-47AC-844F-8BA0240C65DE

Q33340568-482D780D-B297-409C-9339-B4213D47E21C

Q33340568-BB852712-7B5B-4241-9D1E-C03AF22E075F

Q33340568-C7C6A540-DF48-4BC1-AB3D-951E9A10D1C6

Q33340568-CB1FB002-13A7-4ED9-91C8-8CDAF8326253

Q33340568-F03D3037-0BFF-4AD3-9E67-7AA5DEE4D01E

Q33340568-F3AA8094-40CD-45FB-87CF-D94743DB3DCC

P304

Q33340568-8C5D74EA-92D7-4A65-84C0-51F596E0E90E

P31

Q33340568-3E6BE89E-EFF0-49B3-A780-50A852E02592

P356

Q33340568-5F8FA8B7-0E4B-4C26-974E-643BCC18C5E6

P407

Q33340568-C2B3C888-2E00-49F9-868F-3A949EB6ED55

P433

Q33340568-63CA0E43-EF4E-45B5-9C54-6EAAD9A2688A

P478

Q33340568-3556D88C-CC7F-4948-9546-EFA287AE1E2A

P577

Q33340568-86B7ED1A-F0EB-471C-B0C7-55D89EBB9050

P698

Q33340568-F6D2CBBD-D808-4371-B20D-051BFCBC3886

P921

Q33340568-98B35243-AF19-405F-B00D-7E55F649A9B5

Q33340568-AA5DF716-CE30-43C8-9D73-CCE26D4D24F8

P356

P1433

Journal of Clinical Oncology

P1476

Phase II/III trial of etoposid ...... ediatric oncology group trial.

@en

P2093

Allen M Goorin

http://www.w3.org/2001/XMLSchema#string

Cindy L Schwartz

http://www.w3.org/2001/XMLSchema#string

Gene P Siegal

http://www.w3.org/2001/XMLSchema#string

Holcombe E Grier

http://www.w3.org/2001/XMLSchema#string

Mark Bernstein

http://www.w3.org/2001/XMLSchema#string

Mark C Gebhardt

http://www.w3.org/2001/XMLSchema#string

Meenakshi Devidas

http://www.w3.org/2001/XMLSchema#string

Michael B Harris

http://www.w3.org/2001/XMLSchema#string

Michael Link

http://www.w3.org/2001/XMLSchema#string

William Ferguson

http://www.w3.org/2001/XMLSchema#string

P304

426-433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.20.2.426

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11786570

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

phase III clinical trial